Emergent Biosolutions Inc (EBS)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE
Market Cap: $297.69M
Last updated: Nov 17, 2026 at 11:05 AM ET
Emergent Biosolutions Inc (EBS) Earnings: Report Dates and Results
Emergent Biosolutions (EBS) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Emergent Biosolutions reported EPS of -$0.42, above the -$0.45 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
EBS has an expected report date of Feb 24, 2027.
EBS Earnings Call
The latest EBS earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, EBS beat 20, missed 19 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $110.00M, down 52.4% from $231.10M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.42 | -$0.45 | N/A | +6.67% | Beat | -139.6% | 2 | 1 up, 0 down | Nov 2, 2026 | $110.00M |
| Jun 30, 2026 | $0.60 | $0.11 | $0.11 - $0.11 | +445.45% | Beat | +275.0% | 1 | 0 up, 0 down | Aug 5, 2026 | $234.30M |
| Mar 31, 2026 | $0.21 | -$0.25 | -$0.25 - -$0.25 | +184.00% | Beat | -70.4% | 1 | 0 up, 0 down | Apr 30, 2026 | $156.10M |
| Dec 31, 2025 | -$0.43 | $0.43 | N/A | -201.18% | Miss | N/A | 1 | 0 up, 0 down | Feb 26, 2026 | $148.70M |
| Sep 30, 2025 | $1.06 | -$0.12 | -$0.35 - $0.11 | +983.33% | Beat | -22.6% | 2 | 1 up, 0 down | Oct 29, 2025 | $231.10M |
| Jun 30, 2025 | $0.16 | -$0.49 | -$0.72 - -$0.26 | +132.65% | Beat | N/A | 2 | 0 up, 1 down | Aug 6, 2025 | $140.90M |
| Mar 31, 2025 | $0.71 | $0.44 | N/A | +61.36% | Beat | +20.3% | 1 | 0 up, 1 down | May 7, 2025 | $222.20M |
| Dec 31, 2024 | -$0.58 | -$0.50 | -$0.64 - -$0.07 | -16.50% | Miss | N/A | 2 | 0 up, 0 down | Mar 3, 2025 | $194.70M |
| Sep 30, 2024 | $1.37 | $0.14 | -$0.21 - $0.49 | +878.57% | Beat | N/A | 2 | 0 up, 0 down | Nov 6, 2024 | $293.80M |
| Jun 30, 2024 | -$2.32 | -$0.97 | -$0.97 - -$0.92 | -139.18% | Miss | N/A | 2 | 0 up, 0 down | Aug 6, 2024 | $254.70M |
| Mar 31, 2024 | $0.59 | -$0.83 | -$0.83 - -$0.83 | +171.08% | Beat | N/A | 1 | 0 up, 0 down | May 1, 2024 | $300.40M |
| Dec 31, 2023 | -$0.77 | -$0.19 | -$0.33 - $0.07 | -305.26% | Miss | N/A | 3 | 0 up, 0 down | Mar 6, 2024 | N/A |
| Sep 30, 2023 | -$5.08 | -$0.54 | -$0.62 - $0.06 | -840.74% | Miss | N/A | 3 | 0 up, 0 down | Nov 7, 2023 | $519.30M |
| Jun 30, 2023 | -$1.06 | -$0.62 | -$0.89 - -$0.21 | -70.97% | Miss | N/A | 3 | 0 up, 1 down | Aug 8, 2023 | $978.00M |
| Mar 31, 2023 | -$3.17 | -$1.34 | -$1.76 - -$0.80 | -136.57% | Miss | -1861.1% | 5 | 1 up, 0 down | May 9, 2023 | $307.70M |
| Dec 31, 2022 | -$0.31 | $0.04 | -$0.16 - $0.45 | -875.00% | Miss | -106.9% | 5 | 0 up, 0 down | Feb 27, 2023 | N/A |
| Sep 30, 2022 | -$1.27 | -$0.13 | -$0.48 - $0.26 | -876.92% | Miss | N/A | 6 | 0 up, 0 down | Nov 8, 2022 | $239.90M |
| Jun 30, 2022 | -$0.86 | $0.40 | -$0.22 - $1.31 | -315.00% | Miss | -360.6% | 6 | 0 up, 0 down | Aug 1, 2022 | $242.70M |
| Mar 31, 2022 | $0.18 | $0.13 | -$0.07 - $0.36 | +38.46% | Beat | -88.2% | 6 | 2 up, 0 down | Apr 28, 2022 | $307.50M |
| Dec 31, 2021 | $4.50 | $4.27 | $3.17 - $4.77 | +5.39% | Beat | +22.6% | 6 | 0 up, 1 down | Feb 24, 2022 | $3.50B |
| Sep 30, 2021 | -$0.36 | $2.28 | $2.15 - $2.73 | -115.79% | Miss | -116.4% | 6 | 0 up, 0 down | Nov 4, 2021 | $329.00M |
| Jun 30, 2021 | $0.33 | $1.56 | $1.03 - $2.03 | -78.85% | Miss | -83.3% | 6 | N/A | Jul 29, 2021 | $397.50M |
| Mar 31, 2021 | $1.53 | $1.17 | $0.85 - $1.57 | +30.77% | Beat | +15200.0% | 7 | N/A | Apr 29, 2021 | $343.00M |
| Dec 31, 2020 | $3.67 | $3.19 | $2.59 - $3.86 | +15.05% | Beat | +133.8% | 7 | N/A | Feb 18, 2021 | $990.10M |
| Sep 30, 2020 | $2.19 | $2.15 | $1.93 - $2.46 | +1.86% | Beat | +81.0% | 7 | N/A | Nov 5, 2020 | N/A |
| Jun 30, 2020 | $1.98 | $0.66 | $0.53 - $0.79 | +200.00% | Beat | +1550.0% | 6 | N/A | Jul 30, 2020 | $394.70M |
| Mar 31, 2020 | $0.01 | $0.01 | -$0.19 - $0.34 | 0.00% | In line | N/A | 7 | N/A | Apr 30, 2020 | $192.50M |
| Dec 31, 2019 | $1.57 | $1.73 | $1.61 - $1.79 | -9.25% | Miss | +109.3% | 7 | N/A | Feb 20, 2020 | $360.40M |
| Sep 30, 2019 | $1.21 | $0.90 | $0.50 - $1.25 | +34.44% | Beat | +120.0% | 7 | N/A | Nov 6, 2019 | $311.80M |
| Jun 30, 2019 | $0.12 | $0.18 | -$0.07 - $0.47 | -33.33% | Miss | -88.8% | 7 | N/A | Aug 1, 2019 | $243.20M |
| Mar 31, 2019 | -$0.13 | $0.18 | -$0.03 - $0.23 | -172.22% | Miss | N/A | 7 | N/A | May 2, 2019 | $190.60M |
| Dec 31, 2018 | $0.75 | $0.65 | $0.49 - $0.77 | +15.38% | Beat | +1.4% | 8 | N/A | Feb 21, 2019 | $270.80M |
| Sep 30, 2018 | $0.55 | $0.61 | $0.44 - $0.72 | -9.84% | Miss | -24.7% | 7 | N/A | Nov 1, 2018 | $173.60M |
| Jun 30, 2018 | $1.07 | $0.93 | $0.61 - $1.11 | +15.05% | Beat | +723.1% | 7 | N/A | Aug 2, 2018 | $220.20M |
| Mar 31, 2018 | -$0.03 | $0.17 | $0.13 - $0.48 | -117.65% | Miss | -110.3% | 6 | N/A | May 3, 2018 | $117.80M |
| Dec 31, 2017 | $0.74 | $0.70 | $0.63 - $0.74 | +5.71% | Beat | 0.0% | 6 | N/A | Feb 22, 2018 | $193.84M |
| Sep 30, 2017 | $0.73 | $0.41 | $0.37 - $0.46 | +78.05% | Beat | +25.9% | 5 | N/A | Nov 2, 2017 | $149.43M |
| Jun 30, 2017 | $0.13 | $0.26 | $0.17 - $0.40 | -50.00% | Miss | N/A | 5 | N/A | Aug 3, 2017 | $100.77M |
| Mar 31, 2017 | $0.29 | $0.30 | N/A | -3.33% | Miss | +81.2% | N/A | N/A | May 4, 2017 | $116.86M |
| Dec 31, 2016 | $0.74 | $0.61 | N/A | +21.31% | Beat | -5.1% | N/A | N/A | Feb 23, 2017 | $151.68M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $1.50, a profit after a loss of $0.94 per share the year before. It was $1.30 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $1.50 | N/A |
| Dec 31, 2024 | -$0.94 | N/A |
| Dec 31, 2023 | -$10.08 | N/A |
| Dec 31, 2022 | -$2.26 | -137.7% |
| Dec 31, 2021 | $6.00 | -23.6% |
| Dec 31, 2020 | $7.85 | +183.4% |
| Dec 31, 2019 | $2.77 | +18.4% |
| Dec 31, 2018 | $2.34 | +23.8% |
| Dec 31, 2017 | $1.89 | +45.4% |
| Dec 31, 2016 | $1.30 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,500 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,473 | 6 | |
| 2026Q2 | Jun 30, 2026 | 5,311 | 7 | |
| 2026Q1 | Mar 31, 2026 | 4,332 | 8 | |
| 2025Q4 | Dec 31, 2025 | 2,889 | 4 | |
| 2025Q3 | Sep 30, 2025 | 4,346 | 6 | |
| 2025Q2 | Jun 30, 2025 | 5,342 | 5 | |
| 2025Q1 | Mar 31, 2025 | 2,064 | 6 | |
| 2024Q4 | Dec 31, 2024 | 5,399 | 6 |
2026Q3 Earnings Call
Opening remarks
Frank Vargo VP and Treasurer Good afternoon, everyone, and thank you for joining us as Emergent discusses its operational and financial results for the third quarter of 2026. As is customary, today's call is open to all participants, is being recorded and is copyrighted by Emergent BioSolutions. In addition to today's press release, a slide presentation accompanying this webcast is available to all webcast participants. Turning to Slide 2. During today's call, Emergent may make projections and other forward-looking statements related to business, future events, prospects or future performance. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. Any forward-looking statements speak only as of the date of this conference call, and except as required by law, Emergent does not undertake to update any forward-looking statements to reflect new information, events or circumstances. Investors should consider this cautionary statement as well as the risk factors identified in Emergent's periodic reports filed with the SEC when evaluating these forward-looking statements. During today's call, Emergent may also discuss certain non-GAAP financial measures that include adjustments to GAAP figures to provide additional transparency regarding the company's operating performance. Please refer to the tables included in today's press release. Turning to Slide 3. The agenda for today's call includes remarks from Joe Papa, President and Chief Executive Officer, who will provide an update on the company's transformation plan, business performance and key highlights. Rich Lindahl, EVP and Chief Financial Officer, will then review the third quarter 2026 financial results and provide an update on full-year 2026 guidance. Joe Papa will conclude with a discussion of the company's key catalysts for growth, followed by a question-and-answer session. Finally, for the benefit of those who may be listening to the replay of this webcast, this call is held and recorded on November 2, 2026. Since that time, Emergent may have made announcements related to topics discussed during today's call. With that, I will now turn the call over to Joe Papa. Joe?
Joseph Papa President and Chief Executive Officer Hello, everyone, and thank you for joining us to discuss Emergent's third quarter 2026 financial results. This is Joe Papa, President and Chief Executive Officer of Emergent. And I'm joined today by Rich Lindahl, our Chief Financial Officer. This afternoon, I will share an update on our multiyear transformation plan, the actions we implemented during the quarter to strengthen the business and the progress we are making across our diversified medical countermeasure and naloxone portfolios. Rich will then review our third quarter financial results and our outlook for the remainder of 2026. I will close with the growth catalysts and priorities that will guide us as we finish the year. Then we'll open up the call for Q&A.
Frequently Asked Questions About EBS
When is Emergent Biosolutions's next earnings date?
Emergent Biosolutions's next earnings report is expected for Feb 24, 2027.
Did EBS beat earnings estimates last quarter?
Yes. Emergent Biosolutions reported EPS of -$0.42 for the quarter ended Sep 30, 2026, above the -$0.45 estimate, a 6.67% surprise.
What EPS do analysts expect from EBS next quarter?
The consensus EPS estimate for Emergent Biosolutions for the quarter ending Dec 31, 2026 is -$0.17 from 4 analysts, with estimates from -$0.22 to -$0.12.
How often does EBS beat earnings estimates?
Emergent Biosolutions beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +199.47%.
EBS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts